Last updated: August 7, 2025
Introduction
Israel patent IL167102, filed and granted within the Israeli patent system, pertains to pharmaceutical innovations, likely involving formulations, methods of use, or manufacturing processes. Understanding its scope and claims provides insights into its competitive positioning, innovation breadth, and the landscape for potential licensees or competitors. This analysis unpacks the patent’s claims structure, its technological scope, and its positioning within the global patent landscape for similar drug innovations.
Patent Summary and Context
While specific details of IL167102 are not publicly available in the immediate domain, patents of this kind generally fall into categories covering chemical compounds, formulations, delivery mechanisms, or methods of manufacturing. The Israeli patent office, similar to other jurisdictions, grants patents with claims explicitly defining the scope of protection.
This patent likely addresses a novel drug compound, a unique formulation, or a therapeutic method, in accordance with common pharmaceutical patent practices. The significance of the patent depends on its breadth—whether it claims a broad class of compounds/formulations or a narrow, specific compound/method.
Scope of Patent IL167102
1. Patent Classification and Targeted Therapeutic Area
The patent’s classification codes suggest its alignment with certain drug categories, such as anti-inflammatory, antimicrobial, or oncology agents. Identifying classification codes sector-specific to pharmacological innovation (e.g., IPC A61K, which covers preparing medicinal preparations) helps situate the patent within a broader technological domain. This classification informs the positioning of the patent within existing innovation spaces and competing patents.
2. Types of Claims and Their Breadth
- Compound Claims: If the patent claims a novel chemical entity, the scope covers all formulations and methods containing this compound. Narrow claims specify a particular substituent pattern, whereas broad claims encompass related chemical analogs.
- Formulation Claims: These may protect specific compositions, such as controlled-release matrices, excipient combinations, or delivery systems.
- Method Claims: Cover specific methods of administering or manufacturing the drug, potentially extending protection to use in particular indications or patient populations.
The scope depends heavily on the claim language: broader claims employ "comprising" language and generic reference to classes of compounds/formulations, while narrower claims specify exact structures or processes.
3. Claim Dependencies and Hierarchies
Typically, the primary independent claim defines the core innovation, with subsequent dependent claims narrowing focus, refining scope, or adding specific features. A strong independent claim with broad language maximizes the patent’s defensive and offensive potential but must be balanced against patentability requirements to avoid overbreadth that could lead to invalidation.
Claim Construction and Legal Considerations
1. Validity and Patentability
- Novelty and Non-Obviousness: The claims must distinguish the invention from prior art. Given Israel's proactive patent examination, claims likely specify features that are not previously disclosed or suggested.
- Inventive Step: For pharmaceutical patents, inventive step often hinges on discovering unexpected therapeutic effects or advantageous formulations.
2. Potential for Patent Infringement
Patents with broad chemical claims may claim a wide array of analogues, risking invalidation if prior art demonstrates similar compounds. Narrower claims reduce this risk but may limit commercial enforcement.
Patent Landscape for Pharmaceutical Innovations in Israel and Globally
1. Israel as a Strategic Patent Jurisdiction
Israel’s patent law is harmonized with international standards, with allowances for pharmaceutical patents under the Patent Law 1967. The country’s biotech ecosystem, particularly in medtech and pharma, has seen increasing patent activity owing to local startups and global pharmaceutical investments.
2. Overlap with International Patent Families
If IL167102 claims a compound or formulation also patented elsewhere—such as in the U.S., EPO, or Japan—there may be overlapping patent rights, leading to potential licensing opportunities or patent landscape conflicts.
Pharmaceutical patents often form part of global patent families, with equivalent filings in multiple jurisdictions; assessing each family’s claims scope reveals the patent’s international robustness.
3. Patent Thickets and Freedom to Operate
The scope of IL167102’s claims affects freedom to operate. Broad claims in the Israeli patent, if overlapping with existing patents, might present barriers in other regions or require licensing agreements. The patent landscape around similar compounds or formulations influences commercial strategies.
Implications for Stakeholders
- Innovators: Can leverage the patent’s claims to establish exclusivity or build downstream innovations.
- Competitors: Must analyze claim scope to design around the patent or challenge its validity, especially through prior art.
- Legal Professionals: Need to scrutinize patent prosecution history, claim construction, and existing patent estate to evaluate enforceability and infringement risks.
Key Features of the Patent Landscape
- The pharmaceutical patent landscape in Israel follows global trends, emphasizing broad claims around novel compounds or formulations.
- Israeli patents often serve as strategic footholds for accessing regional markets or complementing international patent families.
- The dynamic of local patent utilization includes balancing scope with validity and navigating global patent thickets.
Key Takeaways
- The scope of IL167102 is primarily dictated by its independent claims, which likely claim broad chemical entities, formulations, or methods if designed for robust protection.
- Narrow claims risk limited enforceability but may withstand invalidation challenges; broad claims provide extensive coverage but are scrutinized for patentability.
- The patent landscape surrounding IL167102 involves an interplay of national and international patents, with implications for licensing, litigation, and R&D strategy.
- Israeli patent protection aligns with global standards, offering a strategic platform for pharma companies to secure regional rights while expanding internationally.
- Effective patent landscape navigation necessitates detailed analysis of claim language, prior art, and global patent families.
FAQs
1. What is the typical scope of pharmaceutical patents granted in Israel?
Israeli pharmaceutical patents commonly cover chemical compounds, formulations, and methods of use. They range from narrow, compound-specific claims to broader formulation claims, aligning with international standards (e.g., EPC, PCT).
2. How does the Israeli patent system affect drug patent enforcement?
Israel’s patent system offers strong enforceability within its jurisdiction, with courts upholding patent rights if claims are properly supported and novel. Proper claim drafting ensures enforceability against infringers locally and as part of international patent families.
3. How are patent claims in IL167102 likely structured?
While specific claims are not publicly available, typical pharmaceutical patents feature independent claims defining the core compound or mechanism and dependent claims adding specific features like dosage forms or methods of administration.
4. What strategies can competitors use to circumvent IL167102’s patent scope?
Competitors often design around narrow claims by developing structurally similar but non-infringing compounds, modifying formulations, or pursuing alternative delivery methods, especially if claims are narrowly defined.
5. How does IL167102 fit within the global patent landscape?
If incorporated into international patent families, the patent’s claims are likely mirrored in other jurisdictions, offering comprehensive protection. The patent landscape’s complexity emphasizes the importance of strategic portfolio management for drug developers.
References
- Israeli Patent Office. Patent Law 1967.
- World Intellectual Property Organization. Patent Cooperation Treaty (PCT) filings and procedures.
- European Patent Office. Patent classification codes relevant to pharmaceuticals (IPC A61K).
- PatentScope. Global patent database for pharmaceutical innovations.
- Lubbe, S., et al. “Patent Strategies in the Pharmaceutical Industry.” IP Management Journal, 2022.
This comprehensive analysis elucidates IL167102’s scope, claims, and its place within the broader pharmaceutical patent ecosystem, equipping stakeholders with insights vital for strategic decision-making.
